Archive


Category: CatylYm

  • German biotech CatalYm raises €50 million for GDF-15 inhibitor immunotherapy

    CatalYm has closed a €50 million ($59m) series B financing round to fund clinical studies of its immunotherapy targeting Growth Differentiation Factor 15 (GDF-15). The round was led by Vesalius Biocapital III, with participation from Novartis Venture Fund (NVF), Wachstumsfonds Bayern, coparion and founding investors Forbion and BioGeneration Ventures. Founded in 2016 as a spin-out […]